SS Innovations International (NASDAQ: SSII) used two October medical conferences to demonstrate that robotic surgery can be performed at extreme distances, including a cardiac procedure in which the operating surgeon sat roughly 7,500 miles from the patient, according to the company's announcement carried by NEWMEDIAWIRE.
At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, Chairman and Chief Executive Officer Dr. Sudhir Srivastava remotely performed an atrial septal defect procedure on a patient located in Bengaluru, India. The demonstration relied on the company's SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console, the platform the company is positioning as the centerpiece of its remote-surgery strategy.
Four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, spanning urological, colorectal, pediatric and gynecological procedures. By October 23, 2026, the company reported 205 telesurgeries completed with the SSi Mantra system, including cardiac procedures, a cumulative figure that gives investors and clinicians a measurable base for evaluating how quickly the technology is being used.
The significance extends beyond a single demonstration. Remote robotic surgery, if validated, could allow specialist expertise to reach patients far from major medical centers, where access to experienced cardiac, urological or pediatric surgeons is often limited. That prospect matters for hospital systems weighing how to serve underserved regions and for patients who currently face travel or relocation for complex operations. The company's full account of the demonstrations is available through its SS Innovations (NASDAQ: SSII) profile and a detailed https://ibn.fm/EZFDT release summary.
Widespread adoption, however, depends on clinical validation, connectivity and regulatory requirements, the company acknowledged. Those constraints are central to the investment case because a demonstration across thousands of miles does not by itself establish routine clinical use. Reliable, low-latency networks must be available at both ends of a procedure, and regulators in each market must clear the system for the specific uses proposed.
In the United States, SS Innovations is pursuing Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027. The company noted that the timeline remains subject to the FDA's review, a caveat that leaves the U.S. commercial opportunity contingent on a process outside its control.
For readers and industry observers, the October events offer an early look at how robotic surgery may be delivered rather than merely performed. If the approach clears clinical and regulatory hurdles, it could reshape referral patterns and expand the reach of specialized surgical teams. Further details are available in the company's Read More coverage, and investors should note the full terms of use and disclaimers published at https://IBN.ai/Disclaimer.
